Current Urology Reports

, Volume 11, Issue 4, pp 276–285 | Cite as

Minimally Invasive Therapies for Chronic Pelvic Pain Syndrome

  • Salim A. Wehbe
  • Jennifer Y. Fariello
  • Kristene Whitmore


Chronic pelvic pain syndrome (CPPS) is a common problem among men and women worldwide. It is a symptoms-complex term for interstitial cystitis/painful bladder syndrome in women and chronic prostatitis/chronic pelvic pain syndrome in men. Patients often present with a combination of lower urinary tract symptoms with pelvic pain and sexual dysfunction. No gold standard exists for diagnosis or treatment of CPPS. The diagnosis is often challenging and is determined by elimination. Multiple treatment modalities exist, ranging from physical therapy to surgery. We discuss minimally invasive therapies for treatment of this complex of symptoms. Although data suggest reasonable efficacy of several medications, multimodal therapy remains the mainstay of treatment. We review the following minimally invasive therapeutic modalities: dietary modifications, physical therapy, mind-body therapies, medical therapy, intravesical therapies, trigger point injections, botulinum toxin injections to the pelvic floor, and neuromodulation. We report data supporting their use and efficacy and highlight the limitations of each.


Chronic pelvic pain syndrome Interstitial cystitis Minimally invasive therapy Chronic prostatitis 



The authors wish to thank Pamela Fried of Drexel University College of Medicine’s Academic Publishing Services for editorial assistance.


No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. 1.
    Eisenberg ER, Moldwin RM: Etiology: where does prostatitis stop and interstitial cystitis begin? World J Urol 2003, 21:64–69.CrossRefPubMedGoogle Scholar
  2. 2.
    Heim LJ: Evaluation and differential diagnosis of dyspareunia. Am Fam Physician 2001, 63:1535–1544.PubMedGoogle Scholar
  3. 3.
    Metts JF: Interstitial cystitis: urgency and frequency syndrome. Am Fam Physician 2001, 64:1199–1206.PubMedGoogle Scholar
  4. 4.
    Nickel JC: Interstitial cystitis—an elusive clinical target? J Urol 2003,170:816–817.CrossRefPubMedGoogle Scholar
  5. 5.
    Berry SH, Stoto MA, Elliott M, et al.: Prevalence of interstitial cystitis/painful bladder syndrome in the United States. The Rand Interstitial Cystitis Epidemiology (RICE) study. Poster presented at the Annual Meeting of the American Urological Association. Chicago, IL; April 25–30, 2009.Google Scholar
  6. 6.
    Rosenberg MT, Page S, Hazzard MA: Prevalence of interstitial cystitis in a primary care setting. Urology 2007, 69(Suppl 4):48–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Nickel JC, Downey J, Hunter D, Clark J: Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001, 165:842–845.CrossRefPubMedGoogle Scholar
  8. 8.
    Roberts RO, Jacobson DJ, Girman CJ, et al.: Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002, 168:2467–2471.CrossRefPubMedGoogle Scholar
  9. 9.
    Forrest JB, Nickel JC, Moldwin RM: Chronic prostatitis/chronic pelvic pain and male interstitial cystitis: Enigmas and opportunities. Urology 2007, 69(Suppl 4):60–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Nazif O, Teichman J, Gebhart GF: Neural upregulation in interstitial cystitis. Urology 2007, 69(Suppl 4):24–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Clemens JQ, Markossian T, Calhoun EA: Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology 2009, 73:743–746.CrossRefPubMedGoogle Scholar
  12. 12.
    ●●Nickel JC, Shoskes D: Phenotypic approach to the management of chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep 2009, 10:307–312. This phenotypic approach may represent the most complete therapeutic tool to treat patients with UCPPS. CrossRefPubMedGoogle Scholar
  13. 13.
    Herati A, Shorter B, Tai J, et al.: Differences in food sensitivities between IC/PBS and CP/CPPS. J Urol 2009, 181(Suppl 4):60.Google Scholar
  14. 14.
    ● Nickel JC, Baranowski AP, Pontari M, et al.: Management of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome who have failed traditional management. Rev Urol 2007, 9:63–72. This important review outlines innovative treatment strategies for patients with CPPS. Google Scholar
  15. 15.
    Potts JM, O’Dougherty E: Pelvic floor physical therapy for patients with prostatitis. Curr Urol Rep 2000, 1:155–158.CrossRefPubMedGoogle Scholar
  16. 16.
    Shoskes DA, Berger R, Elmi A, et al.: Muscle tenderness in men with chronic prostatitis/chronic pelvic pain syndrome: The chronic prostatitis cohort study. J Urol 2008, 179:556–560.CrossRefPubMedGoogle Scholar
  17. 17.
    Hetrick DC, Glazer H, Liu YW, et al.: Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case control study. Neurourol Urodyn 2006, 25:46–49.CrossRefPubMedGoogle Scholar
  18. 18.
    Weiss JM: Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001, 166:2226–2231.CrossRefPubMedGoogle Scholar
  19. 19.
    Oyama IA, Rejba A, Lukban JC, et al.: Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004, 64:862–865.CrossRefPubMedGoogle Scholar
  20. 20.
    FitzGerald MP, Anderson RU, Potts J, et al.: Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009, 182:570–580.CrossRefPubMedGoogle Scholar
  21. 21.
    Ger GC, Wexner SD, Jorge JM, et al.: Evaluation and treatment of chronic intractable rectal pain—a frustrating endeavor. Dis Colon Rectum 1993, 36:139–145.CrossRefPubMedGoogle Scholar
  22. 22.
    Heah SM, Ho YH, Tan M, Leong AF: Biofeedback is effective treatment for levator ani syndrome. Dis Colon Rectum 1997, 40:187–189.CrossRefPubMedGoogle Scholar
  23. 23.
    Astin JA: Mind-body therapies for the management of pain. Clin J Pain 2004, 20: 27–32.CrossRefPubMedGoogle Scholar
  24. 24.
    van Tulder MW, Ostelo R, Vlaeyen JW, et al.: Behavioral treatment for chronic low back pain: a systematic review within the framework of the Cochrane Back Review Group. Spine (Phila PA 1976) 2000, 25:2688–2699Google Scholar
  25. 25.
    Bergeron S, Binik YM, Khalifé S, et al.: A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain 2001, 91:297–306.CrossRefPubMedGoogle Scholar
  26. 26.
    Mehik A, Hellström P, Sarpola A, et al.: Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. BJU Int 2001, 88:35–38.CrossRefPubMedGoogle Scholar
  27. 27.
    Spinhoven P, Linssen AC: Behavioral treatment of chronic low back pain: Relation of coping strategy use to outcome. Pain 1991, 45:29–34.CrossRefPubMedGoogle Scholar
  28. 28.
    McCracken LM, Turk LC: Behavioral and Cognitive-Behavioral treatment for chronic pain: Outcome, predictors of outcome and treatment process. Spine (Phila Pa 1976) 2002, 27:2564–2573.Google Scholar
  29. 29.
    Weijenborg PT, Greeven A, Dekker FW, et al.: Clinical course of chronic pelvic pain in women. Pain 2007, 132(Suppl 1):S117–S123.CrossRefPubMedGoogle Scholar
  30. 30.
    Fall M, Baranowski AP, Elneil S, et al.: EAU Guidelines on chronic pelvic pain. Eur Urol 2010, 57:35–48.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen R. Nickel JC: Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2003, 61:1156–1159CrossRefPubMedGoogle Scholar
  32. 32.
    Honjo H, Kamoi K, Naya Y, et al.: Effects of acupuncture for chronic pelvic pain syndrome with intrapelvic venous congestion: preliminary results. Int J Urol 2004, 11:607–612.CrossRefPubMedGoogle Scholar
  33. 33.
    Lee SW, Liong ML, Yuen KH, et al.: Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain. Am J Med 2008, 121:79.e1–e7PubMedGoogle Scholar
  34. 34.
    Lee SH, Lee BC: Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. Urology 2009, 73:1036–1041.CrossRefPubMedGoogle Scholar
  35. 35.
    ●● Murphy AB, Macejko A, Taylor A, Nadler RB: Chronic prostatitis: management strategies. Drugs 2009, 69:71–84. This is a very well-structured review of management strategies for CP/CPPS. CrossRefPubMedGoogle Scholar
  36. 36.
    Nickel J, Zadeikis N, Spivey M: Clinical significance of antimicrobial therapy in chronic prostatitis associated with non-traditional uropathogens. J Urol 2005, 73:S30.Google Scholar
  37. 37.
    Alexander RB, Propert KJ, Schaeffer AJ, et al.: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004, 141:581–589.PubMedGoogle Scholar
  38. 38.
    Theoharides TC, Sant GR: Immunomodulators for the treatment of interstitial cystitis. Urology 2005, 65:633–638.CrossRefPubMedGoogle Scholar
  39. 39.
    Soucy F, Grégoire M: Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol 2005, 173:841–843.CrossRefPubMedGoogle Scholar
  40. 40.
    Buffington CA: Re: cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 2006, 176:838.CrossRefPubMedGoogle Scholar
  41. 41.
    Nickel JC, Pontari M, Moon T, et al.: A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003, 169:1401–1405.CrossRefPubMedGoogle Scholar
  42. 42.
    Nickel JC, Forrest JB, Tomera K, et al.: Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 2005, 173:1252–1255.CrossRefPubMedGoogle Scholar
  43. 43.
    Mishra VC, Browne J, Emberton M: Role of alpha-blockers in type III prostatitis: a systematic review of the literature. J Urol 2007, 177:25–30.CrossRefPubMedGoogle Scholar
  44. 44.
    Theoharides TC, Sant GR: Hydroxyzine therapy for interstitial cystitis. Urology 1997, 49(Suppl 5A):108–110CrossRefPubMedGoogle Scholar
  45. 45.
    Bouchelouche K, Nordling J, Hald T, Bouchelouche P: The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 2001, 166:1734–1737.CrossRefPubMedGoogle Scholar
  46. 46.
    Shoskes DA, Zeitlin SI, Shahed A, Rajfer J: Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999, 54:960–963.CrossRefPubMedGoogle Scholar
  47. 47.
    Rugendorff EW, Weidner W, Ebeling L, Buck AC: Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993, 71:433–438.CrossRefPubMedGoogle Scholar
  48. 48.
    Dawson TE, Jamison J: Intravesical treatments for painful bladder syndrome/ interstitial cystitis. Cochrane Database Syst Rev 2007, Issue 4:CD006113.Google Scholar
  49. 49.
    Rössberger J, Fall M, Peeker R: Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 2005, 39:73–77.CrossRefPubMedGoogle Scholar
  50. 50.
    Davis EL, El Khoudary SR, Talbott EO, et al.: Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol 2008, 179:177–185.CrossRefPubMedGoogle Scholar
  51. 51.
    Payne CK, Mosbaugh PG, Forrest JB, et al.: Intravesical resiniferatoxin for the treatment of interstitial cystitis: A randomized, double-blind, placebo controlled trial. J Urol 2005, 173:1590–1594.CrossRefPubMedGoogle Scholar
  52. 52.
    Anderson VR, Perry CM: Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs 2006, 66:821–835.CrossRefPubMedGoogle Scholar
  53. 53.
    Nickel JC, Moldwin R, Lee S, et al.: Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int 2009, 103:910–918.CrossRefPubMedGoogle Scholar
  54. 54.
    Theoharides TC, Whitmore K, Stanford E, et al.: Interstitial cystitis: bladder pain & beyond. Expert Opin Pharmacother 2008, 9:2979–2994.CrossRefPubMedGoogle Scholar
  55. 55.
    Evans RJ: Treatment approaches for interstitial cystitis: multimodal therapy. Rev Urol 2002, 4(Suppl 1):S16–S20.PubMedGoogle Scholar
  56. 56.
    Kang YS, Jeong SY, Cho HJ, et al.: Transanally injected triamcinolone acetonide in levator syndrome. Dis Colon Rectum 2000, 43:1288–1291.CrossRefPubMedGoogle Scholar
  57. 57.
    Langford CF, Udvari Nagy S, Ghoniem GM: Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn 2007, 26:59–62.CrossRefPubMedGoogle Scholar
  58. 58.
    Abbott JA, Jarvis SK, Lyons SD, et al.: Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006, 108:915–923.CrossRefPubMedGoogle Scholar
  59. 59.
    Rao SS, Paulson J, Mata M, Zimmerman B: Clinical trial: effects of botulinum toxin on levator ani syndrome—a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009, 29:985–991.CrossRefPubMedGoogle Scholar
  60. 60.
    Chuang YC, Chancellor MB: The application of botulinum toxin in the prostate. J Urol 2006, 176(6 Pt 1):2375–2382.CrossRefPubMedGoogle Scholar
  61. 61.
    Moldwin RM, Evans RJ, Stanford EJ, Rosenberg MT: Rational approaches to the treatment of patients with interstitial cystitis. Urology 2007, 69(Suppl 4):73–81.CrossRefPubMedGoogle Scholar
  62. 62.
    Peters KM, Carey JM, Konstandt, DB: Sacral neuromodulation for the treatment of interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 2003, 14:223–228.CrossRefPubMedGoogle Scholar
  63. 63.
    Brookoff DM, Bennett DS: Neuromodulation in intractable interstitial cystitis and related pelvic pain syndromes. Pain Med 2006, 7(S1):166–184CrossRefGoogle Scholar
  64. 64.
    Everaert K, Devulder J, De Muynck M, et al.: The pain cycle: implications for the diagnosis and treatment of pelvic pain syndromes. Int Urogynecol J Pelvic Floor Dysfunct 2001, 12:9–14.CrossRefPubMedGoogle Scholar
  65. 65.
    Siegel S, Paszkiewicz E, Kirkpatrick C, et al.: Sacral nerve stimulation in patients with chronic intractable pelvic pain. J Urol 2001, 166:1742–1745.CrossRefPubMedGoogle Scholar
  66. 66.
    Maher CF, Carey MP, Dwyer PL, Schluter PL: Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol 2001, 165:884–886.CrossRefPubMedGoogle Scholar
  67. 67.
    Comiter CV: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 2003, 169:1369–1373.CrossRefPubMedGoogle Scholar
  68. 68.
    Peters KM, Konstandt D: Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis. BJU Int 2004, 93:777–779.CrossRefPubMedGoogle Scholar
  69. 69.
    Whitmore KE, Payne CK, Diokno AC, Lukban JC: Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial. Int Urogynecol J Pelvic Floor Dysfunct 2003,14:305–308.CrossRefPubMedGoogle Scholar
  70. 70.
    Hellstrom WJ, Schmidt RA, Lue TF, Tanagho EA: Neuromuscular dysfunction in nonbacterial prostatitis. Urology 1987, 30:183–188.CrossRefPubMedGoogle Scholar
  71. 71.
    Mayer RD, Howard FM: Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain. Neurotherapeutics 2008, 5:107–113.CrossRefPubMedGoogle Scholar
  72. 72.
    Congregado Ruiz B, Pena Outeiriño XM, Campoy Martínez P, et al.: Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms. Eur Urol 2004, 45:65–69.CrossRefPubMedGoogle Scholar
  73. 73.
    Groen J, Amiel C, Bosch JL: Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator. Neurourol Urodyn 2005, 24:226–230.CrossRefPubMedGoogle Scholar
  74. 74.
    Peters KM, Feber KM, Bennett RC: Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn 2005, 24:643–647.CrossRefPubMedGoogle Scholar
  75. 75.
    Peters KM, Killinger KA, Boguslawski BM, Boura JA: Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 2009 Sep 28 (Epub ahead of print).Google Scholar
  76. 76.
    Carmel M, Lebel M, Tu LM: Pudendal nerve neuromodulation with neurophysiology guidance: a potential treatment option for refractory chronic pelvi-perineal pain. Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:613–616.CrossRefPubMedGoogle Scholar
  77. 77.
    Rowe E, Smith C, Laverick L, et al.: A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. J Urol 2005, 173:2044–2047.CrossRefPubMedGoogle Scholar
  78. 78.
    Paick JS, Lee SC, Ku JH: More effects of extracorporeal magnetic innervations and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study. Prostate Cancer Prostatic Dis 2006, 9:261–265.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Salim A. Wehbe
    • 1
  • Jennifer Y. Fariello
    • 1
  • Kristene Whitmore
    • 1
  1. 1.Department of Obstetrics and GynecologyDrexel University College of Medicine, Pelvic and Sexual Health InstitutePhiladelphiaUSA

Personalised recommendations